Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 8%
Buy 23%
Hold 62%
Sell 8%
Strong Sell 0%

Bulls say

Amgen's management anticipates over 20% growth in research and development spending by 2025, indicating a commitment to innovation and advancing its therapeutic pipeline. Notably, Uplizna sales surged approximately 58% from the previous quarter and 40% year-over-year, reflecting robust demand and market performance. Additionally, the combination of strong sales growth and pipeline advancements supports the potential for multiple expansion, with an estimated enterprise value (EV) to projected 2026 EBITDA ratio of around 13 times.

Bears say

Amgen's financial outlook appears concerning due to declining sales from key products, particularly as many of its blockbuster drugs face increasing competition and potential biosimilar threats. Additionally, the company's substantial research and development expenditures may strain profitability if newer therapies fail to meet market expectations. Finally, recent acquisitions, while bolstering the product portfolio, have also resulted in increased debt levels, which could impact financial flexibility moving forward.

Amgen (AMGN) has been analyzed by 13 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 23% recommend Buy, 62% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 13 analysts, Amgen (AMGN) has a Hold consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $313.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $313.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.